Account
Inquiry
Tirzepatide, also known as LY3298176, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is primarily developed for research into type 2 diabetes treatment, showing superior efficacy in glucose control and weight loss compared to other agents like Dulaglutide. With a greater affinity for GIP receptors, Tirzepatide mimics natural GIP actions, making it a valuable compound for scientific studies.
This peptide features a sequence similar to semaglutide, with PEG modification on the lys side chain to enhance water solubility. Its main physiological role involves acting as a dual agonist, which has entered clinical stages for type 2 diabetes research. Additionally, Tirzepatide has demonstrated potential in weight loss studies for overweight individuals, with phase 3 trials ongoing. In the SURMOUNT-1 trial, participants experienced significant weight reduction over 72 weeks.
As a once-weekly administered agent, Tirzepatide combines the effects of GIP and GLP-1 into a single molecule, representing an innovative approach in diabetes research. It is supplied as a white powder in vials, ensuring high stability and ease of handling for laboratory use. Proper storage is crucial: keep in a cold, dry, dark place, avoid repeated freeze-thaw cycles, and minimize air and light exposure to maintain integrity.
For researchers seeking tirzepatide near me, our product offers reliable quality and consistency, supporting various experimental needs from milligrams to larger quantities. Always handle with care and adhere to safety protocols, as this is for research purposes only and not intended for personal use.
